LOS ANGELES, April 22, 2005 (PRIMEZONE) -- Universal Detection Technology (OTCBB:UDTT) today announced that it has appointed Dr. Donald V. Cramer to its scientific advisory board. Dr. Cramer will help shape and maintain a focused research and development strategy for the company and will provide a wealth of expertise in seeking government and private grants and awards for future and present research projects.
"The addition of Dr. Cramer to our scientific advisory team adds significant experience in public health and administration. His experience in writing and receiving government grants will aid the Company as we continue to market our technology to both the private and public sectors," says Jacques Tizabi, UDTT's chairman and CEO.
The company is planning to utilize Dr. Cramer's expertise to evaluate the feasibility of new research projects and to monitor and apply for relevant government grants for existing and new research, development, and commercialization undertakings.
Donald V. Cramer, D.V.M., Ph.D.
Dr. Donald V. Cramer has years of professional experience including academic and administrative responsibilities with various public and private organizations. He served as the Acting Director of Surgical Research and the Director of Transplantation Biology at the Cedars-Sinai Medical Center in Los Angeles from 1989 to 1992. His other employment activities include membership at the National Institutes of Health reviewer reserve, National Center for Research Resources. From 1978-1989 Dr. Cramer served as the Associate Professor of Pathology (with Tenure) at University of Pittsburgh School of Medicine. From 1998 to 2003 he has been a research professor at the departments of Cardiothoracic Surgery and Molecular Microbiology and Immunology. During the same period he has also acted as the Director of Research at the Department of Cardiothoracic Surgery. Dr. Cramer has been a consultant to the Department of Abdominal Organ Transplantation from 2003 to present.
Dr. Cramer's major areas of research interest and experience include Pathology, Immunology, Genetics, and Transplantation Biology. He has received several grants and fellowships from the National Institutes of Health, American Cancer Society, BRSG Research Support, Sterling Drug Company, American Heart Association, United Liver Association, the Du Pont and Merck Pharmaceutical Company, and many other organizations.
About Universal Detection Technology
Universal Detection Technology (UDTT), founded in 1973, is a developer of monitoring technologies, including bio-terrorism detection devices. Management believes that the Company's technology, together with third party technologies and devices, has positioned it to capitalize on growth and value opportunities related to Homeland Security. UDTT, in cooperation with NASA's Jet Propulsion Laboratory (JPL), has developed a bio-terror `smoke' detector, which combines JPL's spore detection technology with UDTT's aerosol capture device.
For more information, please visit http://udtt.invrel.net or http://www.udetection.com.
Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties include, among other things, the funding of amounts of capital adequate to provide for our working capital needs and our timely repayment of debt, our ability to timely and cost effectively complete the development and testing of our products targeted to the bio-chemical market, our ability to commercially produce our products on a profitable basis, commercial acceptance of our products, product price volatility, product demand, market competition and general economic conditions, and other factors described in the Company's filings with the Securities and Exchange Commission. We undertake no obligation and do not intend to revise or update publicly any forward looking statements for any reason.